Cardiovascular and Interventional Radiological Society of Europe (CIRSE)’s Post

⚽ Ahead of a big weekend for English football fans, it's your Weekly Medtech round-up! 💸 Quest Diagnostics have announced a deal to acquire LifeLabs Medical Laboratory Services from OMERS in a deal worth approximately $985M https://t.ly/NGTLS 📰 The Wall Street Journal are reporting that Baxter International Inc. are considering the sale of its kidney care unit Vantive, to private equity firm The Carlyle Group in a deal worth over $4B https://t.ly/wxkpI ✅ Roche received CE marking for its continuous glucose monitor this week, paving the way for the solution to launch in select European markets in the coming months. Will this approval disrupt the majority role Abbott and Dexcom play in the CGM market? https://t.ly/xliCb ⚠ Pulse Biosciences, Inc. has announced its plan to pursue pre-market approval for its CellFX cardiac clamp technology, delaying a program which was previously on the 501(k) pathway. This shift has caused experts to suggest the device will now not reach market before late 2026 https://t.ly/Dndy1

🌟 We are thrilled to have advised our long-standing client, Siemens Healthineers, on their acquisition of Advanced Accelerator Applications, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. The Linklaters team was led by Timo Engelhardt and Dr. Ruprecht Frhr. von Maltzahn. Many thanks to the Siemens Healthineers team and everyone involved for their exceptional collaboration! Read more 👉 https://lnkd.in/gXM2vYQi

Celebrating my new certification! On Mindray Chemiluminescence immunoassay(CLIA) model Cl-2600I Series

ZYTIGA (Abiraterone) and XTANDI (enzalutamide) are standards of care options for the first line mCRPC patients progressing on androgen deprivation therapy (ADT). No combination has been so far approved to increase the radiological progression-free survival (rPFS) and overall survival (OS) in first-line mCRPC.  Data from a Phase III PEACE-3 (NCT02194842) comparative study of enzalutamide vs a combination of Radium-223 (Ra223) investigating whether the combination improves cancer progression over enzalutamide alone in patients with mCRPC was presented in the Proffered Paper Session at the ESMO - European Society for Medical Oncology 2024. Unlock Comprehensive Analysis and Expert Insights with DelveInsight's Exclusive ESMO 2024 Coverage @ https://lnkd.in/gZam4XRc #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical

Kuros Biosciences is pleased to announce an exclusive strategic agreement with the Medtronic spinal division. The five-year sales agency agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market, underscoring a shared commitment to expanding access to Kuros’ pioneering MagnetOsᵀᴹ bone grafting technology.   Chris Fair, Chief Executive Officer of Kuros Biosciences, commented: “What started as a trial agreement has now evolved into a strategic alliance with Medtronic reflecting an important milestone for Kuros. This agreement will also help us drive the scaling up process, further optimize our operating leverage, and continue our rapid revenue growth both with Medtronic and in our own direct channels. “   To read the full press release, click here → https://lnkd.in/eVtVimGw

2024 has already been a "blink and you'll miss a radiopharma deal" kind of year. If Trump's term does loosen up M&A in 2025, watch out for more. There are plenty of acquisition targets about, each offering different pieces of the RLT pie: isotopes, chelator technology, novel delivery vehicles or binders, target expertise or even combination modalities (like DDR agents). https://lnkd.in/e_aCj4dJ

Exciting news from European Hematology Association (EHA) 2024! CARsgen Therapeutics' CT071 is showing promising results in treating relapsed/refractory multiple myeloma (RRMM). #CT071, a CAR T-cell therapy targeting GPRC5D, is produced using CARsgen's CARcelerateTM platform, accelerating manufacturing to under 2 days for more effective CAR T cells. Preliminary data from the first-in-human trial (#NCT05838131) showed a 90% overall response rate (ORR), with 100% MRD negativity among evaluable patients. Despite some Grade 3 or higher hematologic toxicities, all treatment-related adverse events were resolved. CT071's expedited production and promising efficacy offer hope for RRMM patients, especially those previously treated with BCMA-targeting therapies. With the ongoing Phase I trial, CARsgen Therapeutics is poised to make a significant impact in the multiple myeloma treatment landscape. Get detailed analysis of the abstract here: https://lnkd.in/eVb7TqPa Stay tuned for more updates on this innovative therapy! #CARsgenTherapeutics #CT071 #MultipleMyeloma #CARcelerate #EHA2024 #ClinicalTrials #healthcare #business #clinicalstudies #results #phases #top #abstracts #pharmaceutical #hematology #eha24 #cart #celltherapy

Unlock the truth behind Peptides and Human Cellular Tissue Products in this comprehensive virtual masterclass. Get ready to revolutionize your practice with the All Things Peptides Virtual Masterclass! Happening June 7-8, this event is packed with insights, strategies, and practical applications in peptides and advanced biologics. Why Attend? * Access Recordings: Can’t make it live? All ticket holders get access to recordings of all sessions, presentation slides, and event materials. * Comprehensive Knowledge: Dive deep into peptides and advanced biologics with practical implementation strategies. * Empowerment & Growth: MedMasters aims to educate and empower you with resources to deliver superior therapies, revolutionizing patient outcomes and opening doors to new revenue streams. Don’t miss out! Secure your spot now and elevate your practice. Learn More: https://lnkd.in/ecQzyDFM

Agenda Launch! - The 7th TPD & Induced Proximity Summit Boston - October 28th - 31st 2024. - Download the agenda here https://ter.li/ptotjn Please ignore the Link preview as LinkedIn is displaying this incorrectly. With one of the best agenda's to date, I'm incredibly excited to once again be working on The 7th TPD & Induced Proximity Summit Boston, the largest and leading gathering of world leading experts working in this incredibly exciting and rapidly developing space. (Call me biased, but i think this is definitely the best TPD meeting in the world). Once again uniting a who's who of the field covering the end to end developments across all modalities - I can't wait to see you all there and would like to say a huge thankyou to our expert speakers and partners from: Promega Corporation NEOsphere Biotechnologies GmbH SCIEX LifeSensors, Inc WuXi AppTec Sai Life Sciences Ltd BioDuro-Sundia Charnwood Discovery NanoImaging Services Serán BioScience NanoTemper Technologies Biotheryx, Inc. Orionis Biosciences Biortus DeepKinase 旦白志 Arvinas C4 Therapeutics, Inc. Kymera Therapeutics Monte Rosa Therapeutics Nurix Therapeutics PhoreMost Ltd University of Dundee FDA A-Alpha Bio Asha Therapeutics Astellas Pharma AstraZeneca Booster Therapeutics Novartis Pfizer Cullgen Inc. Degron Therapeutics Foghorn Therapeutics Inc. Genentech GSK Sibylla Biotech The Francis Crick Institute AbbVie Amgen Avilar Therapeutics Many more companies tagged in the comment below due to the tag limit! https://lnkd.in/efCqEqeJ #TheTPDSummit #7thTPD #targetedproteindegradation #TPD #degraders #PROTAC #MolecularGlue #Inducedproximity